Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
Australia
Novartis Investigative Site, Darlinghurst, New South Wales Novartis Investigative Site, Melbourne, Victoria France
Novartis Investigative Site, Montpellier Novartis Investigative Site, Nancy Novartis Investigative Site, Rennes Germany
Novartis Investigative Site, Bochum Novartis Investigative Site, Essen Novartis Investigative Site, Mainz Novartis Investigative Site, Ulm Italy
Novartis Investigative Site, Genova, GE Novartis Investigative Site, Milan, MI Spain
Novartis Investigative Site, Barcelona Novartis Investigative Site, Córdoba Novartis Investigative Site, Madrid Novartis Investigative Site, Valencia Switzerland
Novartis Investigative Site, Bern Novartis Investigative Site, Lausanne Novartis Investigative Site, Zurich